Novellus’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Novellus is a clinical-stage biotechnology company that designs and develops functional therapeutics for patients with cancer and orphan diseases. Read more

130 Followers on Owler
130 Followers on Owler
130 Followers on Owler
130 Followers on Owler

Novellus is a clinical-stage biotechnology company that designs and develops functional therapeutics for patients with cancer and orphan diseases. Read more

Michael Vidne's photo - CEO of Novellus

CEO

Michael Vidne

CEO Approval Rating

90/100

Founded:

2011

Status:

PrivateIndependent Company

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Guardant Health is seen as one of Novellus's biggest rivals. Guardant Health is headquartered in Redwood City, California, and was founded in 2013. Like Novellus, Guardant Health also works within the Biotechnology sector. Guardant Health generates ∞% the revenue of Novellus.

Biocept is seen as one of Novellus's top competitors. Biocept was founded in 1997, and its headquarters is in San Diego, California. Biocept operates in the Biotechnology industry. Biocept has 28 more employees than Novellus.

Pyxis Oncology is one of Novellus's top rivals. Pyxis Oncology is a Private company that was founded in Boston, Massachusetts in 2018. Pyxis Oncology operates in the Biotechnology industry. Pyxis Oncology has 14 fewer employees vs. Novellus.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Illumina a competitor of Novellus?

Acquisitions

No recent acquisitions found related to Novellus

Novellus Funding History

$10M$12.5M$18.5M$75.5M

Since Novellus was founded in 2011, it has participated in 4 rounds of funding. In total Novellus has raised $75.5M. Novellus' last funding round was on Sep 2020 for a total of $57.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series C
Sep 2020
$57M

Pontifax

Equity
Apr 2018
$6M
Equity
Jun 2016
$2.5M
Equity
Dec 2015
$10M

Since Novellus was founded in 2011, it has participated in 4 rounds of funding. In total Novellus has raised $75.5M. Novellus' last funding round was on Sep 2020 for a total of $57.0M

Investments

No recent investments found related to Novellus

Novellus News

September 23, 2020Jewish Business News

Israel's Novellus Hits $57 Million Series C Financing For Cancer Treatments

Novellus, Ltd., an Israeli clinical-stage biotechnology company focused on precision oncology (treatm... See more »
September 22, 2020Endpoints News

Israeli biotech raises $57M to go where current BRAF inhibitors can't, with backing from Novartis, SR One

For the blockbuster potential of Novartis' Tafinlar and Pfizer's Braftovi, all the BRAF inhibitors on... See more »
September 21, 2020Globes

Precision oncology co Novellus raises $57m

The Israeli company's lead program PLX-8394 is a BRAF inhibitor with a differentiated mechanistic pro... See more »
December 17, 2018BioPortfolio

Cancer Genetics Terminates Proposed Merger with NovellusDx

Cancer Genetics NasdaqCGIX a leader in enabling precision medicine for immunooncology and genomic med... See more »
September 20, 2018Proactive Investors

Cancer Genetics CEO says merger with NovellusDx to speed up enrollment in cancer-focused trials

The combined company will have extensive expertise in multiple myeloma, lymphomas, lung, and breast c... See more »

Novellus Blogs

May 13, 2020NovellusDx Blog

CRISPR-Directed In Vitro Gene Editing of Plasmid DNA Catalyzed by Cpf1 (Cas12a) Nuclease and a Mammalian Cell-Free Extract

The CRISPR Journal (2018) Brett M. Sansbury^1, Amanda M. Wagner^1, Erez Nitzan^2, Gabi Tarcic^2, and ... See more »
May 13, 2020NovellusDx Blog

A Novel System for Functional Determination of Variants of Uncertain Significance using Deep Convolutional Neural Networks

Lior Zimmerman, Ori Zelichov, Arie Aizenmann, Zohar Barbash, Michael Vidne & Gabi Tarcic Abstract... See more »
February 14, 2019NovellusDx Blog

Why geneticists stole cancer research even though cancer is primarily a signaling disease.

In a focus article recently published in Science Signaling (Sci. Signal.  22 Jan 2019), Michael Yaffe... See more »
February 14, 2019NovellusDx Blog

NovellusDx presenting a groundbreaking AI framework for VUS determination

NovellusDx team will be attending the AACR 2019 annual meeting and will present a poster titled: “Acc... See more »
January 29, 2019NovellusDx Blog

The EU Patent Office grants NovellusDx a patent for: METHODS FOR DETERMINING DRUG RESPONSE OF PATIENT SPECIFIC MUTATIONS

The EU Patent Office grants NovellusDx patent for: "METHODS FOR DETERMINING DRUG RESPONSE OF PATIENT ... See more »
October 21, 2018NovellusDx Blog

Michael Vidne, CCO, presents “Using Deep Learning to Predict Activity and Drug Response of Unknown Mutations” at NVIDIA’s GTC conference

NovellusDx was selected to present its Deep Learning machine learning framework to predict the activi... See more »
October 21, 2018Novellus Blog

Michael Vidne, CCO, presents "Using Deep Learning to Predict Activity and Drug Response of Unknown Mutations" at NVIDIA's GTC conference

NovellusDx was selected to present its Deep Learning machine learning framework to predict the activi... See more »

Novellus Press Releases

October 22, 2015PRWEB

Persomics enters into Functional Genomics Screening Agreement with NovellusDx

Persomics, a growing company with innovative solutions that miniaturize, accelerate and increase the ... See more »
January 26, 2015PR NEWSWIRE

NovellusDx Highlights Precision Cancer Analysis Platform at Personalized Medicine World Conference 2015

JERUSALEM, Jan. 26, 2015 /PRNewswire/ -- NovellusDx, the leading Precision Cancer Analysis company de... See more »

Social Media

Headquarters

Hadassah Medical Center Campus Jerusalem Bio-Park 5th floor

Jerusalem, Jerusalem District91120

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Novellus is a clinical-stage biotechnology company that designs and develops functional therapeutics for patients with cancer and orphan diseases. Novellus was founded in 2011. Novellus' headquarters is located in Jerusalem, Jerusalem District, IL 911...

CEO

Novellus's CEO, Michael Vidne, currently has an approval rating of 90%. Novellus's primary competitors are Guardant Health, Biocept & Pyxis Oncology.

Website

novellus.bio

Frequently Asked Questions about Novellus

  1. When was Novellus founded?

    Novellus was founded in 2011
  2. Who is Novellus's CEO?

    Novellus's CEO is Michael Vidne
  3. How much revenue does Novellus generate?

    Novellus generates $ < 1M in revenue
  4. How much funding does Novellus have?

    Novellus has historically raised $75.5M in funding
  1. Where is Novellus's headquarters?

    Novellus's headquarters is in Jerusalem Jerusalem District, IL
  2. How many employees does Novellus have?

    Novellus has 60 employees
  3. What sector does Novellus operate in?

    Novellus is in Pharmaceuticals, Biotechnology
  4. Who are Novellus's competitors?

    Novellus's top competitors are Guardant Health, Biocept, Pyxis Oncology